Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2022 Feb 10;22(1):171.
doi: 10.1186/s12913-022-07557-7.

"It was difficult to offer same day results": evaluation of community-based point-of-care testing for sexually transmitted infections among youth using the GeneXpert platform in Zimbabwe

Kevin Martin  1   2 , Chido Dziva Chikwari  3   4 , Constance R S Mackworth-Young  3 , Mutsawashe Chisenga  4 , Tsitsi Bandason  4 , Ethel Dauya  4 , Ioana D Olaru  3   4 , Suzanna C Francis  5 , Constancia Mavodza  5   6 , Portia Nzombe  4 , Rangarirayi Nyamwanza  4 , Fadzanai Hove  4 , Maureen Tshuma  4 , Anna Machiha  7 , Katharina Kranzer #  3   4   8 , Rashida A Ferrand #  3   4
Affiliations
Randomized Controlled Trial

"It was difficult to offer same day results": evaluation of community-based point-of-care testing for sexually transmitted infections among youth using the GeneXpert platform in Zimbabwe

Kevin Martin et al. BMC Health Serv Res. .

Abstract

Background: Point-of-care testing for sexually transmitted infections (STIs) may improve diagnosis and treatment of STIs in low- and middle-income counties. We explored the facilitators and barriers to point-of-care testing for Chlamydia trachomatis (CT) and Neisseria gonorrhoea (NG) for youth in community-based settings in Zimbabwe.

Methods: This study was nested within a cluster randomised trial of community-based delivery of integrated HIV and sexual and reproductive health services for youth aged 16 to 24 years. On-site CT/NG testing on urine samples using the Xpert® CT/NG test was piloted in four intervention clusters, with testing performed by service providers. On-site testing was defined as sample processing on the same day and site as sample collection. Outcomes included proportion of tests processed on-site, time between sample collection and collection of results, and proportion of clients receiving treatment. In-depth interviews were conducted with nine service providers and three staff members providing study co-ordination or laboratory support to explore facilitators and barriers to providing on-site CT/NG testing.

Results: Of 847 Xpert tests, 296 (35.0%) were performed on-site. Of these, 61 (20.6%) were positive for CT/NG; one (1.6%) received same day aetiological treatment; 33 (54.1%) presented later for treatment; and 5 (8.2%) were treated as a part of syndromic management. There was no difference in the proportion of clients who were treated whether their sample was processed on or off-site (64% (39/61) vs 60% (66/110); p = 0.61). The median (IQR) number of days between sample collection and collection of positive results was 14 (7-35) and 14 (7-52.5) for samples processed on and off-site, respectively, The interviews revealed four themes related to the provision of on-site testing associated with the i) diagnostic device ii) environment, iii) provider, and iv) clients. Some of the specific barriers identified included insufficient testing capacity, inadequate space, as well as reluctance of clients to wait for their results.

Conclusions: In addition to research to optimise the implementation of point-of-care tests for STIs in resource-limited settings, the development of new platforms to reduce analytic time will be necessary to scale up STI testing and reduce the attrition between testing and treatment.

Trial registration: Registered in clinical trials.gov ( NCT03719521 ).

Keywords: Africa; Community-based settings; Gonorrhoea; Point-of-care tests; Sexually transmitted infections; Youth; chlamydia.

PubMed Disclaimer

Conflict of interest statement

RAF reports grants from the Wellcome Trust, during the conduct of the study. All other authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Photograph of testing set-up
Fig. 2
Fig. 2
Flow chart for testing and treatment of CT/NG infections
See this image and copyright information in PMC

References

    1. Rowley J, Vander Hoorn S, Korenromp E, Low N, Unemo M, Abu-Raddad LJ, et al. Chlamydia, gonorrhoea, trichomoniasis and syphilis: global prevalence and incidence estimates, 2016. Bull World Health Organ. 2019;97(8):548–62P. doi: 10.2471/BLT.18.228486. - DOI - PMC - PubMed
    1. Torrone EA, Morrison CS, Chen PL, Kwok C, Francis SC, Hayes RJ, et al. Prevalence of sexually transmitted infections and bacterial vaginosis among women in sub-Saharan Africa: an individual participant data meta-analysis of 18 HIV prevention studies. PLoS Med. 2018;15(2):e1002511. doi: 10.1371/journal.pmed.1002511. - DOI - PMC - PubMed
    1. Martin K, Olaru ID, Buwu N, Bandason T, Marks M, Dauya E, et al. Uptake of and factors associated with testing for sexually transmitted infections in community-based settings among youth in Zimbabwe: a mixed-methods study. Lancet Child Adolesc Health. 2021;5:122–132. doi: 10.1016/S2352-4642(20)30335-7. - DOI - PMC - PubMed
    1. Fleming DT, Wasserheit JN. From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV infection. Sex Transm Infect. 1999;75(1):3–17. doi: 10.1136/sti.75.1.3. - DOI - PMC - PubMed
    1. World Health Organization . Guidelines for the management of sexually transmitted infections. 2004. - PubMed

Publication types

Associated data